Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived...

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• PG2 is a botanical drug primarily composed of Astragalus polysaccharides (APS).
• Previous clinical studies suggest PG2's potential in hematopoiesis and alleviating cancer-related fatigue.
• Systematic analyses of PG2's biological functions remain limited.

Purpose of the Study:

• To evaluate the quality and consistency of PG2 from three different product batches using microarray-based expression profiling.
• To investigate the biological mechanisms of PG2 through an integrative molecular analysis approach.
• To identify PG2-induced gene expression signatures in HL-60 leukemia cells.

Main Methods:

• Microarray-based gene expression profiling was employed to analyze PG2.
• An integrative molecular analysis approach was used to examine PG2-induced signatures in HL-60 leukemia cells.
• Hierarchical clustering of correlation coefficients facilitated quantitative analysis of gene expression signatures.

Main Results:

• PG2 product batches exhibited high quality and consistency.
• PG2 demonstrated functional equivalence in modulating immune and hematopoietic systems across batches.
• PG2 combined with doxorubicin showed a synergistic effect on inducing cell death in HL-60 cells.
• Five genes (IL-8, MDM4, BCL2, PRODH2, BIRC5) were identified as associated with doxorubicin within the PG2 signature.

Conclusions:

• Gene expression profiling provides a quantitative measure for herbal medicine quality and consistency.
• PG2 exhibits immune modulatory roles and synergistic effects with doxorubicin in cancer treatment.
• PG2 represents a promising botanical agent for cancer therapy, particularly through immune modulation.